Treatment of skeletally mature ovariectomized rhesus monkeys with PTH(1-84) for 16 months increases bone formation and density and improves trabecular architecture and biomechanical properties at the lumbar spine

被引:40
作者
Fox, John
Miller, Michael A.
Newman, Michael K.
Turner, Charles H.
Recker, Robert R.
Smith, Susan Y.
机构
[1] NPS Pharmaceut Inc, Salt Lake City, UT 84108 USA
[2] Indiana Univ, Dept Orthopaed Surg, Indianapolis, IN USA
[3] Creighton Univ, Osteoporosis Res Ctr, Omaha, NE 68178 USA
[4] Charles River Labs, Preclin Serv, Montreal, PQ, Canada
关键词
ovariectomized primate; PTH; bone turnover markers; bone densitometry; bone histomorphometry; bone strength;
D O I
10.1359/JBMR.061101
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Histomorphometric studies of treatments for osteoporosis in humans are restricted to iliac crest biopsies. We studied the effects of PTH(1-84) treatment at the lumbar spine of skeletally mature ovariectomized rhesus monkeys. PTH increased bone turnover, rapidly normalized BMD, and increased vertebral compressive strength. PTH increased trabecular bone volume primarily by increasing trabecular number by markedly increasing intratrabecular tunneling.
引用
收藏
页码:260 / 273
页数:14
相关论文
共 36 条
[31]   Six-month daily administration of parathyroid hormone and parathyroid hormone-related protein peptides to adult ovariectomized rats markedly enhances bone mass and biomechanical properties: A comparison of human parathyroid hormone 1-34, parathyroid hormone-related protein 1-36, and SDZ-parathyroid hormone 893 [J].
Stewart, AF ;
Cain, RL ;
Burr, DB ;
Jacob, D ;
Turner, CH ;
Hock, JM .
JOURNAL OF BONE AND MINERAL RESEARCH, 2000, 15 (08) :1517-1525
[32]   Biomechanics of bone: Determinants of skeletal fragility and bone quality [J].
Turner, CH .
OSTEOPOROSIS INTERNATIONAL, 2002, 13 (02) :97-104
[33]  
Turner CH, 2001, ADV EXP MED BIOL, V496, P165
[34]   SPECIES-DIFFERENCES IN THE BINDING-KINETICS OF 25-HYDROXYVITAMIN-D3 TO VITAMIN-D BINDING-PROTEIN [J].
VIETH, R ;
KESSLER, MJ ;
PRITZKER, KPH .
CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, 1990, 68 (10) :1368-1371
[35]  
VIETH R, 1987, J MED PRIMATOL, V16, P349
[36]  
FDA GUIDANCE 1994 GU